Cargando…
Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspension...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927114/ https://www.ncbi.nlm.nih.gov/pubmed/33672363 http://dx.doi.org/10.3390/antibiotics10020225 |
_version_ | 1783659618702983168 |
---|---|
author | Mack, Ines Sharland, Mike Brussee, Janneke M. Rehm, Sophia Rentsch, Katharina Bielicki, Julia |
author_facet | Mack, Ines Sharland, Mike Brussee, Janneke M. Rehm, Sophia Rentsch, Katharina Bielicki, Julia |
author_sort | Mack, Ines |
collection | PubMed |
description | Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspensions would be expected not to keep to the specified storage conditions. We aimed to assess the stability of both ingredients in liquid formulations and dispersible tablets, combined with nationally representative data on access to appropriate storage. Degradation of amoxicillin (AMX) and clavulanic-acid (CLA) was measured in suspensions and dispersible tablets commercially available in Switzerland at different ambient temperatures (8 °C vs. 28 °C over 7 days, and 23 °C vs. 28 °C over 24 h, respectively). Data on access to refrigeration and electricity were assessed from the USAID-funded Demographic and Health Survey program. In suspensions, CLA degraded to a maximum of 12.9% (95% CI −55.7%, +29.9%) at 8°C and 72.3% (95% CI −82.8%, −61.8%) at a 28 °C ambient temperature during an observation period of 7 days. Dispersible tablets were observed during 24 h and CLA degraded to 15.4% (95% CI −51.9%, +21.2%) at 23 °C and 21.7% (−28.2%, −15.1%) at a 28 °C ambient temperature. There is relevant degradation of CLA in suspensions during a 7-day course. To overcome the stability challenges for all active components, durable child-appropriate formulations are needed. Until then, prescribers of AMC suspensions or pharmacists who sell the drug need to create awareness for the importance of proper storage conditions regarding effectiveness of both antibiotics and this recommendation should be reflected in the WHO Essential Medicines List for children. |
format | Online Article Text |
id | pubmed-7927114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79271142021-03-04 Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations Mack, Ines Sharland, Mike Brussee, Janneke M. Rehm, Sophia Rentsch, Katharina Bielicki, Julia Antibiotics (Basel) Article Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspensions would be expected not to keep to the specified storage conditions. We aimed to assess the stability of both ingredients in liquid formulations and dispersible tablets, combined with nationally representative data on access to appropriate storage. Degradation of amoxicillin (AMX) and clavulanic-acid (CLA) was measured in suspensions and dispersible tablets commercially available in Switzerland at different ambient temperatures (8 °C vs. 28 °C over 7 days, and 23 °C vs. 28 °C over 24 h, respectively). Data on access to refrigeration and electricity were assessed from the USAID-funded Demographic and Health Survey program. In suspensions, CLA degraded to a maximum of 12.9% (95% CI −55.7%, +29.9%) at 8°C and 72.3% (95% CI −82.8%, −61.8%) at a 28 °C ambient temperature during an observation period of 7 days. Dispersible tablets were observed during 24 h and CLA degraded to 15.4% (95% CI −51.9%, +21.2%) at 23 °C and 21.7% (−28.2%, −15.1%) at a 28 °C ambient temperature. There is relevant degradation of CLA in suspensions during a 7-day course. To overcome the stability challenges for all active components, durable child-appropriate formulations are needed. Until then, prescribers of AMC suspensions or pharmacists who sell the drug need to create awareness for the importance of proper storage conditions regarding effectiveness of both antibiotics and this recommendation should be reflected in the WHO Essential Medicines List for children. MDPI 2021-02-23 /pmc/articles/PMC7927114/ /pubmed/33672363 http://dx.doi.org/10.3390/antibiotics10020225 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mack, Ines Sharland, Mike Brussee, Janneke M. Rehm, Sophia Rentsch, Katharina Bielicki, Julia Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title | Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title_full | Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title_fullStr | Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title_full_unstemmed | Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title_short | Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations |
title_sort | insufficient stability of clavulanic acid in widely used child-appropriate formulations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927114/ https://www.ncbi.nlm.nih.gov/pubmed/33672363 http://dx.doi.org/10.3390/antibiotics10020225 |
work_keys_str_mv | AT mackines insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations AT sharlandmike insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations AT brusseejannekem insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations AT rehmsophia insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations AT rentschkatharina insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations AT bielickijulia insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations |